Journals / Journal of Clinical and Experimental Investigations / 2010 / Cilt: 1 - Sayı: 3

Otoimmun romatizmal hastalıklarda hızlanmış damar sertleşmesi

Accelerated atherosclerosis in autoimmune rheumatic diseases

Pages
232–234
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to determine whether these autoimmune rheumatic diseases are also associated with accelerated atherosclerosis and its manifestations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atherosclerosis is increasingly considered an immune system-mediated process of the vascular system.
📊
Key Findings & Data:The reason for accelerated atherosclerosis in patients with autoimmune rheumatic diseases remains unclear.
💡
Conclusion & Impact:Further studies are needed to determine whether these autoimmune rheumatic diseases are also associated with accelerated atherosclerosis and its manifestations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atherosclerosis is increasingly considered an immune system-mediated process of the vascular system. Autoantibodies, autoantigens, pro-inflammatory cytokines and infectious agents play a role in that process. Autoimmunity-related cardiovascular disease and atherosclerosis are important clinical problems. The reason for accelerated atherosclerosis in patients with autoimmune rheumatic diseases remains unclear. Some cases of autoimmunity-related cardiovascular disease may be more related to thrombosis than atherosclerosis. Although, mechanisms causing the increased risk are not precisely clarified, a combination of traditional and nontraditional risk factors, including inflammation appears to be of importance. Further studies are needed to determine whether these autoimmune rheumatic diseases are also associated with accelerated atherosclerosis and its manifestations.

Özet

Ateroskleroz artan bir şekilde dammar sisteminin immune system aracılı bir oluşumu olarak algılanmaktadır. Otoantikorlar, otoantijenler, yangı artırıcı sitokinler ve enfeksiyöz etkenler bu oluşumda rol alabilir. Ototimmunite bağlantılı kalp-damar hastalıkları ve damar sertliği önemli klinik sorunlardır. Otoimmun romatizmal hastalıklarda hızlanmış damar sertliği gelişmesinin nedeni açık değildir. Bazı otoimmunite ilişkili kalp-damar sorunları damar sertliğinden ziyade tromboz ile ilişkilidir. Artan riskin mekanizmaları net olarak açıklanmamakla birlikte, geleneksel olan ve olmayan risk faktörlerinin - yangı da içlerinde olarak – bir kombinasyonu önemli gözükmektedir. Otoimmun romatizmal hastalıkların hızlanmış damar sertleşmesi ve belirtileri ile birlikte olup olmadığı konusunda yeni araştırmalara gereksinim vardır.

🔖

Cite This Article

VRABIE, C. D., COJOCARU, M., COJOCARU, I. M., SILOSI, I. (2022). Otoimmun romatizmal hastalıklarda hızlanmış damar sertleşmesi. Journal of Clinical and Experimental Investigations, Cilt: 1 - Sayı: 3, 232–234. https://ajindex.com/articles/562069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009
  2. 8 2. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004
  3. 403 3. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004
  4. 109(Suppl I): II-2-II-10 4. Jara LJ, Medina G, Vera-Lastra G, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006
  5. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005
  6. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001
  7. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002
  8. 20 8. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006
  9. 2432 9. Van Doornum S, Mc Coll G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002
  10. Maradit–Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005
  11. del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003
  12. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004
  13. Gerli R, Bocci EB, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008
  14. Nakken B, Szodoray P. Accelerated atherosclerosis in rheumatoid arthritis: rational for mannose-binding lectins? J Rheumatol 2010
  15. Frostegand J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005
  16. 95 16. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 2006
  17. 15(11_suppl): 3-10. 17. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus eryt